Indian Council of Medical Research has said that COVID-19 vaccine Covaxin has equivalent immunogenicity against the UK-variant and circulating strains of SARS-Cov2 in India.
Covaxin is developed by Bharat Biotech in collaboration with ICMR. The UK-variant of SARS-Cov-2 with its all signature mutations were isolated and cultured in the world successfully for the first time at ICMR-NIV which was used for testing.
